Benjamin Mark Schleiff

OverviewAI-generated summary

Benjamin Mark Schleiff's research focuses on the metabolic activation of non-steroidal anti-inflammatory drugs (NSAIDs), particularly diphenylamine derivatives. His work investigates the role of specific cytochrome P450 enzymes, such as CYP2C9 and CYP3A4, in both the bioactivation and detoxification pathways of these compounds. Schleiff has examined how halogenation of diphenylamine NSAIDs influences their potential for bioactivation, a process that can lead to adverse drug reactions. His methodologies include advanced analytical techniques like liquid chromatography and fluorescence spectrometry to study chemical models and biological samples. Schleiff has published three papers and has a citation count of 27, with an h-index of 3. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Grover P. Miller and Gunnar Boysen.

Metrics

• h-index: 3
• Publications: 3
• Citations: 27